Compare AstraZeneca plc (AZN) vs Dow Jones Industrial Average ETF (DIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Dow Jones Industrial Average ETF — how do they compare? AstraZeneca plc trades at $158.51 (market cap $248.14B), while Dow Jones Industrial Average ETF trades at $537.49. The key difference: AstraZeneca plc pays a 2.01% dividend while Dow Jones Industrial Average ETF pays none, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | DIA | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $542.79 |
52-Week Low | $147.06 | $444.64 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
DIA (SPDR Dow Jones Industrial Average ETF) trades at $538.46, showing minimal daily movement with a slight 0.1% decline. The technical outlook remains bullish with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent dividend distributions highlight the fund's income-generating capabilities, with upcoming payments scheduled through mid-2026.
The ETF offers diversified exposure to Dow Jones blue-chip stocks amid positive market breadth. Key risks include market volatility and geopolitical tensions affecting broad indices. Analyst sentiment remains constructive given the fund's defensive positioning and institutional inflows into core index heavyweights.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →
